NASDAQ:LFCR Lifecore Biomedical (LFCR) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free LFCR Stock Alerts $6.60 -0.04 (-0.60%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$6.44▼$6.7450-Day Range$5.01▼$8.4052-Week Range$4.06▼$11.45Volume110,906 shsAverage Volume184,572 shsMarket Capitalization$199.97 millionP/E RatioN/ADividend YieldN/APrice Target$9.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Lifecore Biomedical alerts: Email Address Lifecore Biomedical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside44.0% Upside$9.50 Price TargetShort InterestBearish6.30% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.42) to ($0.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.46 out of 5 starsMedical Sector707th out of 915 stocksPharmaceutical Preparations Industry324th out of 424 stocks 3.3 Analyst's Opinion Consensus RatingLifecore Biomedical has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageLifecore Biomedical has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.30% of the float of Lifecore Biomedical has been sold short.Short Interest Ratio / Days to CoverLifecore Biomedical has a short interest ratio ("days to cover") of 9.5.Change versus previous monthShort interest in Lifecore Biomedical has recently increased by 5.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLifecore Biomedical does not currently pay a dividend.Dividend GrowthLifecore Biomedical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LFCR. Previous Next N/A News and Social Media Coverage Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lifecore Biomedical insiders have not sold or bought any company stock.Percentage Held by Insiders14.61% of the stock of Lifecore Biomedical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions83.36% of the stock of Lifecore Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lifecore Biomedical are expected to grow in the coming year, from ($0.42) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lifecore Biomedical is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lifecore Biomedical is -1.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap ProfitsClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.Secure Your Spot Now About Lifecore Biomedical Stock (NASDAQ:LFCR)Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Read More LFCR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LFCR Stock News HeadlinesApril 20, 2024 | seekingalpha.comWhite Falcon Capital - Lifecore Biomedical: Potential For Rapid Growth In Earnings And FCF SurgeApril 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Lifecore Biomedical, Inc. - LFCRApril 28, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 19, 2024 | prnewswire.comROSEN, SKILLED INVESTOR COUNSEL, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDCApril 19, 2024 | msn.comLifecore Biomedical gets Nasdaq notice regarding delayed quarterly reportApril 19, 2024 | globenewswire.comLifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly ReportApril 17, 2024 | msn.comLifecore Biomedical (LFCR) Price Target Decreased by 11.11% to 8.16April 12, 2024 | prnewswire.comLFCR INVESTOR NEWS: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation - LFCR, LNDCApril 28, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Lifecore Biomedical, Inc. - LFCRApril 11, 2024 | businesswire.comROSEN, A TOP RANKED LAW FIRM, Encourages Lifecore Biomedical Inc. f/k/a Landec Corporation Investors to Inquire About Securities Class Action Investigation – LFCR, LNDCApril 11, 2024 | finance.yahoo.comDo You Believe in the Upside Trajectory of Lifecore Biomedical (LFCR)?April 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Lifecore Biomedical, Inc. - LFCRApril 1, 2024 | finance.yahoo.comLifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date ProgressMarch 28, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of InvestorsMarch 28, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of InvestorsMarch 28, 2024 | businesswire.comLifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsMarch 28, 2024 | finanznachrichten.deLifecore Biomedical, Inc.: Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business UpdateMarch 26, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Lifecore Biomedical, Inc. (LFCR) on Behalf of InvestorsMarch 26, 2024 | globenewswire.comLifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business UpdateMarch 24, 2024 | stockhouse.comLifecore Class Action Lawsuit Investigation News - Potential to Make Claim, Recover Losses, Contact Johnson Fistel, LLPMarch 24, 2024 | businesswire.comLifecore Class Action Lawsuit Investigation News – Potential to Make Claim, Recover Losses, Contact Johnson Fistel, LLPMarch 21, 2024 | businesswire.comLifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsMarch 21, 2024 | businesswire.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against Lifecore Biomedical, Inc. (LFCR)March 21, 2024 | marketwatch.comLifecore Shares Slide After Strategic Review Ends With No DealMarch 20, 2024 | msn.comWhy Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionMarch 20, 2024 | finanznachrichten.deLifecore Biomedical, Inc.: Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023See More Headlines Receive LFCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lifecore Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/28/2024Fiscal Year End5/31/2024Next Earnings (Estimated)6/06/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LFCR CUSIPN/A CIK1005286 Webwww.lifecore.com Phone(800) 454-1355Fax650-368-9818Employees459Year FoundedN/APrice Target and Rating Average Stock Price Target$9.50 High Stock Price Target$10.00 Low Stock Price Target$9.00 Potential Upside/Downside+44.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$103.27 million Price / Sales1.94 Cash FlowN/A Price / Cash FlowN/A Book Value($0.14) per share Price / Book-47.11Miscellaneous Outstanding Shares30,322,000Free Float25,892,000Market Cap$199.97 million OptionableOptionable Beta1.03 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. James G. Hall (Age 61)CEO, President & Director Comp: $523.6kMr. John D. Morberg (Age 60)Executive VP & CFO Comp: $520.82kDr. Albert D. Bolles Ph.D. (Age 66)President of Curation Foods, Inc. Comp: $1.34MMr. Steve W. LaningaVice President of OperationsDr. Kipling Thacker Ph.D. (Age 69)VP & Chief Scientist Mr. Aaron PerlitshDirector of Internal Audit & Chief Compliance OfficerMr. Darren M. HieberSenior Vice President of Corporate Development & PartnershipsMs. Kara MorleySenior Vice President of Human ResourcesMs. Jackie Q. KleckerExecutive VP & GMMr. Matt AugustsonSenior Vice President of Information TechnologyMore ExecutivesKey CompetitorsTrevi TherapeuticsNASDAQ:TRVIZevra TherapeuticsNASDAQ:ZVRARigel PharmaceuticalsNASDAQ:RIGLOrganigramNASDAQ:OGIAlimera SciencesNASDAQ:ALIMView All CompetitorsInstitutional OwnershipGreenhaven Road Investment Management L.P.Bought 173,623 shares on 2/15/2024Ownership: 7.806%Visionary Wealth AdvisorsSold 4,130 shares on 2/14/2024Ownership: 1.640%DCF Advisers LLCBought 138,930 shares on 2/13/2024Ownership: 0.856%Cove Street Capital LLCSold 195,292 shares on 2/12/2024Ownership: 3.002%Simplex Trading LLCSold 8,000 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions LFCR Stock Analysis - Frequently Asked Questions Should I buy or sell Lifecore Biomedical stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lifecore Biomedical in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" LFCR shares. View LFCR analyst ratings or view top-rated stocks. What is Lifecore Biomedical's stock price target for 2024? 2 brokers have issued 12 month target prices for Lifecore Biomedical's shares. Their LFCR share price targets range from $9.00 to $10.00. On average, they predict the company's stock price to reach $9.50 in the next year. This suggests a possible upside of 44.0% from the stock's current price. View analysts price targets for LFCR or view top-rated stocks among Wall Street analysts. How have LFCR shares performed in 2024? Lifecore Biomedical's stock was trading at $6.19 at the beginning of 2024. Since then, LFCR shares have increased by 6.5% and is now trading at $6.5950. View the best growth stocks for 2024 here. When is Lifecore Biomedical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 6th 2024. View our LFCR earnings forecast. What guidance has Lifecore Biomedical issued on next quarter's earnings? Lifecore Biomedical issued an update on its FY 2024 earnings guidance on Monday, April, 1st. The company provided EPS guidance of for the period. The company issued revenue guidance of $125.0 million-$130.0 million, compared to the consensus revenue estimate of $123.6 million. How do I buy shares of Lifecore Biomedical? Shares of LFCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LFCR) was last updated on 4/28/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHis win rate puts Warren Buffett to shame… Investing DailyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lifecore Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
